CEL-SCI

Yahoo Finance • 12 months ago

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock

VIENNA, Va., November 16, 2023--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 2,490,000 shares of its common st... Full story

Yahoo Finance • 2 years ago

CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock

VIENNA, Va., April 28, 2023--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public off... Full story

Yahoo Finance • 2 years ago

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch VIENNA, Va., August 08, 2022--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the appoin... Full story